2021-08-28
“In pancreatic cancer treatment, no matter how excellent a drug may be, it is difficult to deliver it to cancer cells in the first place. Many studies aimed to improve drug delivery in the past five years, but all of them failed. Nanoliposomal irinotecan (nal-IRI, brand name: Onivyde) using new nanotechnology showed successful results in a phase 3 trial in the second-line treatment of...
